View:

Download DOC

Download PDF

Download XLS

Table of Contents

Table of Contents

                                                                 Exhibit 99.1



         GTX, INC. ENTERS INTO A WORLDWIDE COLLABORATION, LICENSE AND
CO-PROMOTION AGREEMENT WITH ORTHO BIOTECH PRODUCTS, L.P., FOR ANDARINE, A
SELECTIVE ANDROGEN RECEPTOR MODULATOR (SARM)

Memphis, Tenn. - March 17, 2004 -- GTx Inc. (Nasdaq: GTXI), a biopharmaceutical
company dedicated to the development and commercialization of therapeutic
products for men's health, announced today that GTx has entered into a joint
collaboration and license agreement with Ortho Biotech Products L.P. for
andarine, its most advanced SARM (Selective Androgen Receptor Modulator)
compound, and specified backup SARM compounds. SARMs bind to testosterone
receptors in the body and have the potential to affect muscle, bone, sexual
function and mood. Andarine is currently being tested in human clinical trials.

"This agreement combines GTx's expertise in SARMs and men's health with the
world class research and marketing capabilities of Ortho Biotech. Andarine could
become the first product in this new class of drugs," said Mitchell Steiner, MD,
FACS, Vice-Chairman and CEO of GTx.

Under the terms of the agreement, GTx will receive an upfront licensing fee,
additional licensing fees and milestone payments up to $82 million based on
andarine and up to $45 million for each additional licensed compound achieving
specific clinical development decisions or obtaining regulatory approvals.
Johnson & Johnson Pharmaceutical Research & Development will be responsible for
further clinical development and expenses, and Ortho Biotech will be responsible
for commercialization and expenses.

Once approved, Ortho Biotech will exclusively market andarine in the U.S. and
markets outside the U.S. Under the agreement, GTx has the option to co-promote
andarine and the other licensed SARM compounds to urologists in the U.S. for
uses specifically related to men's health. GTx will receive up to double digit
royalties on all sales, as well as additional royalty payments in excess of 20%
on all co-promoted sales to urologists in the U.S.




"We believe that andarine is the first SARM to have successfully entered human
clinical trials in the U.S.," said Dr. Steiner. "To date, GTx has completed
several Phase I clinical trials, and with its new partner, plans to initiate a
Phase II clinical trial of andarine in 2004."

Androgen receptors, to which testosterone binds, are found throughout the body
in both men and women. The binding of testosterone to these receptors has
potential effects of building muscle and bone, improving sexual function and
positively effecting mood and libido. The unwanted effects of testosterone are
the potential for increased risk to the prostate, liver and cardiovascular
systems. GTx has designed its SARMs to bind to the androgen receptor in a manner
that maximizes the beneficial effects and minimizes the unwanted effects of
testosterone.

Conference Call

There will be a conference call today at 11:00 a.m. EST to discuss GTx's
agreement with Ortho Biotech. If you would like to participate in the call,
please dial 800-915-4836 from the United States or Canada or 973-317-5319 from
outside North America. A playback of this call will be available today from
approximately 1:00 p.m. EST through March 23, 2004 and may be accessed by
dialing 800-428-6051 from the United States or Canada or 973-709-2089 from
outside North America. The rebroadcast access code is 34480.

About GTx

GTx is a biopharmaceutical company dedicated to the discovery, development and
commercialization of therapeutics primarily related to the treatment of serious
men's health conditions. GTx's drug discovery and development programs are
focused on small molecules that selectively modulate the effects of estrogens
and androgens. GTx currently has two product candidates that are in human
clinical trials. The company is currently conducting clinical trials on
ACAPODENE(TM) (Toremifene Citrate) tablets, its most advanced product candidate,
for two separate indications: (1) a Phase IIb clinical trial to assess the
effect of toremifene in the reduction in the incidence of prostate cancer in men
with precancerous prostate lesions and (2) a pivotal Phase III clinical trial to
assess the effect of toremifene in the treatment of serious side effects of
advanced prostate cancer therapy. GTx is initially developing its second product
candidate, andarine, for the treatment of muscle wasting weight loss, or
cachexia, which occurs from various types of cancer and other chronic diseases.





This press release contains forward-looking statements, including, without
limitation, statements related to potential future licensing fees and milestone
and royalty payments and GTx's current and anticipated clinical trials and
research and development programs. These forward-looking statements are based
upon GTx's current expectations. Forward-looking statements involve risks and
uncertainties. GTx's actual results and the timing of events could differ
materially from those anticipated in such forward-looking statements as a result
of these risks and uncertainties, which include, without limitation, risks that
neither GTx nor its partner will be able to commercialize its product candidates
if preclinical studies do not produce successful results or clinical trials do
not demonstrate safety and efficacy in humans; if third parties do not
manufacture the Company's product candidates in sufficient quantities and at an
acceptable cost, clinical development and commercialization of its product
candidates would be delayed; use of third-party manufacturers may increase the
risk that the Company will not have adequate supplies of its product candidates;
if third parties on whom the Company relies do not perform as contractually
required or expected, the Company may not be able to obtain regulatory approval
for or commercialize its product candidates; the Company is dependent upon
collaborative arrangements to complete the development and commercialization of
some of its product candidates, and these collaborative arrangements may place
the development of its product candidates outside its control, may require it to
relinquish important rights or may otherwise be on terms unfavorable to the
Company; and if the Company is not able to obtain required regulatory approvals,
the Company will not be able to commercialize its product candidates. The final
prospectus filed with the U.S. Securities and Exchange Commission on February 4,
2004 contains under the heading "Risk Factors," and reports that GTx will file
with the U.S. Securities and Exchange Commission will contain, a more
comprehensive description of these and other risks to which GTx is subject. GTx
expressly disclaims any obligation or undertaking to release publicly any
updates or revisions to any forward- looking statements contained herein to
reflect any change in its expectations with regard thereto or any change in
events, conditions or circumstances on which any such statements are based.

         CONTACT: Carney Duntsch, Manager Corporate Communications GTx, Inc. -
                  901-523-9700 ext. 170 or cduntsch@gtxinc.com